Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Scientists discover key molecular events in immune system that contribute to inflammatory bowel disease

Scientists at the Virginia Bioinformatics Institute at Virginia Tech have discovered some of the key molecular events in the immune system that contribute to inflammatory bowel disease.

13 Dec 2010

Prometheus, UCLA collaborate to identify biological markers of mucosal healing in IBD

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and The Regents of the University of California, Los Angeles campus, today announced the execution of an exclusive research agreement that will focus on the identification of biological markers of mucosal healing in patients with Inflammatory Bowel Disease (IBD). The research will be led by Dr. Jonathan Braun, Chair of the Department of Pathology and Laboratory Medicine and a professor of molecular and medical pharmacology, UCLA David Geffen School of Medicine.

10 Dec 2010

Some key molecular events in immune system contribute to inflammatory bowel disease: Scientists

Scientists at the Virginia Bioinformatics Institute at Virginia Tech have discovered some of the key molecular events in the immune system that contribute to inflammatory bowel disease. The results, which help researchers move one step further in their efforts to develop new drugs to treat inflammatory and immune-mediated diseases, are reported in the November 2010 edition of the journal Mucosal Immunology from the Nature Publishing Group.

10 Dec 2010

New endoscope aids in early detection and diagnosis of inflammatory bowel disease.

An international team of researchers led by the University of East Anglia (UEA) have developed a new kind of endoscope to aid the early detection and diagnosis of inflammatory bowel disease.

7 Dec 2010

New tool for predicting disease course in children with Crohn's disease

A new study published in the journal Inflammatory Bowel Diseases develops a computer based visual tool that can be used in “real time” to show pediatric Crohn’s disease (CD) patients’ predicted disease course and how this might be influenced by different treatment options.

6 Dec 2010

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of a new concept in the Current Opinion in Lipidology evaluating oxidized phospholipid analogs as potential treatments for chronic inflammatory diseases.

2 Dec 2010

Worm eggs may heal ulcerative colitis: Research

A new study involving a man who swallowed worm eggs to relieve symptoms of ulcerative colitis sheds light on how worms promote healing in the intestine. The study, published today in Science Translational Medicine, also identifies potential targets for more conventional ways of treating colitis, an inflammatory bowel disease.

2 Dec 2010

IBD patients with hospital-acquired infections experience increased risk of inpatient mortality

Death and length of stay are increased among hospitalized inflammatory bowel disease (IBD) patients who develop hospital-acquired infections, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.

1 Dec 2010

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that initial safety and efficacy data from its ongoing Phase II Study with resminostat, a pan-Histone Deacetylase (HDAC) Inhibitor, in relapsed/refractory Hodgkin Lymphoma (HL) patients after high dose chemotherapy and autologous hematopoietic stem cell transplantation will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, USA.

1 Dec 2010

Kenneth Rainin announces 2011 Innovator Awards Program for Inflammatory Bowel Disease

The Kenneth Rainin Foundation announced today its 2011 Innovator Awards Program for Inflammatory Bowel Disease. The Program, now in its second year, is designed to accelerate the pace of discovery in IBD research.

30 Nov 2010

Immunity-enhancing probiotics may be the best line of defense for good health

Good bacteria, bad bacteria, billions of bacteria—sounds downright germy. But the truth is that research in gut health is germinating more insight into the role bacteria, also known as "probiotics," play in our overall health and wellness.

25 Nov 2010

AADA releases updated position statement on isotretinoin usage

The American Academy of Dermatology Association (AADA) recently updated its position statement on the use of isotretinoin. The position continues to state that patient safety is dermatologists' primary concern and that the AADA is committed to the safe and responsible use of isotretinoin, which is the most effective treatment for severe acne.

23 Nov 2010

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.

19 Nov 2010

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced its financial results in accordance with International Financial Reporting Standards (IFRS) for the first nine months of 2010, which ended on 30 September 2010.

11 Nov 2010

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.

9 Nov 2010

FDA authorizes Athersys' MultiStem Phase II clinical trial for ulcerative colitis

Athersys, Inc. announced today that the U.S. Food and Drug Administration (FDA) has authorized commencement of a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem, Athersys' allogeneic investigational cell therapy product, for the potential treatment of ulcerative colitis.

8 Nov 2010

Santarus's budesonide MMX drug shows positive result for active ulcerative colitis

Santarus, Inc. a specialty biopharmaceutical company, today announced positive top-line results from a second Phase III clinical study evaluating the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate active ulcerative colitis.

8 Nov 2010

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Anti-TNF therapies commonly used to treat rheumatoid arthritis have been found to potentially reduce the risk of developing Alzheimer's dementia among people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Athersys secures three Therapeutic Discovery Project grants

Athersys, Inc. announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation.

4 Nov 2010

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Scientists discover key molecular events in immune system that contribute to inflammatory bowel disease

Prometheus, UCLA collaborate to identify biological markers of mucosal healing in IBD

Some key molecular events in immune system contribute to inflammatory bowel disease: Scientists

New endoscope aids in early detection and diagnosis of inflammatory bowel disease.

New tool for predicting disease course in children with Crohn's disease

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

Worm eggs may heal ulcerative colitis: Research

IBD patients with hospital-acquired infections experience increased risk of inpatient mortality

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

Kenneth Rainin announces 2011 Innovator Awards Program for Inflammatory Bowel Disease

Immunity-enhancing probiotics may be the best line of defense for good health

AADA releases updated position statement on isotretinoin usage

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

FDA authorizes Athersys' MultiStem Phase II clinical trial for ulcerative colitis

Santarus's budesonide MMX drug shows positive result for active ulcerative colitis

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Athersys secures three Therapeutic Discovery Project grants

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in